Skip to main content

Table 1 Demographic, clinical and oral health status data

From: Insights into estrogen impact in oral health & microbiome in COVID-19

Variables

Premenopausal n = 20

Postmenopausal n = 18

Men n = 22

P value

Age

33.55 ± 7.14

56.56 ± 10.25

37.55 ± 10.96

0.0001*

Weight (kg)

73.45 ± 15.95

67.94 ± 13.83

88.95 ± 18.38

0.0004*

Height (m)

1.62 ± 0.06

1.55 ± 0.05

1.75 ± 0.06

0.0001*

Serum estrogen (pg/mL)

88 ± 84

46 ± 56

25 ± 8

0.0001*

Saliva estrogen (pg/mL)

1.19 ± 0.49

0.98 ± 0.42

0.92 ± 0.33

0.1630

Comorbidities

 Yes (%)

7 (35)

14 (77.8)

10 (45.5)

0.0238 + 

 No (%)

13 (65)

4 (22.2)

12 (54.5)

 

 Hypertension

-

4 (28.6)

2 (20)

 

 Diabetes

1 (14.3)

3 (21.4)

1 (10)

 

 Obesity

6 (85.7)

7 (50)

7 (70)

 

Body Mass Index (%)

 Normal Weight

7 (35)

4 (22.2)

3(13.6)

0.4459

 Overweight

7 (35)

7 (38.8)

12 (54.5)

 

 Obesity

6 (30)

7 (38.8)

7 (31.9)

 

SARS-CoV-2

 Viral Load (copies/mL)

8.24 × 106 ± 16 × 106

10.4 × 106 ± 14 × 106

4.9 × 106 ± 10 × 107

0.7225

 High (> 100,000 copies/mL)

15(75%)

11(61.1%)

15(68.2%)

 

 Moderate (10,000 -100,000 copies/mL)

2(10%)

5(27.8%)

4(18.2%)

 

 No detecteda

3(15%)

2(11.1)

3(13.6%)

 

Oral Health

DMF-T

4.6 ± 4.03

7.6 ± 3.27

4.45 ± 3

0.01

CAVITY CARIES (D component)

1.4 ± 2

0.88 ± 1.77

2.09 ± 1.84

0.0483

OHI-S

1.12 ± 0.88

1.52 ± 1.21

1.55 ± 0.79

0.2983

  1. Comparison by groups: + premenopausal women vs postmenopausal women
  2. The Chi square test, one-way ANOVA and *Kruskal–Wallis tests were employed for statistical analysis
  3. aPatients “No detected” had a positive SARS-CoV-2 antigen test